Evolus (EOLS) Expected to Announce Quarterly Earnings on Tuesday

Evolus (NASDAQ:EOLS) is expected to be posting its Q4 2025 results after the market closes on Tuesday, March 3rd. Analysts expect Evolus to post earnings of $0.09 per share and revenue of $89.5810 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

Evolus Price Performance

NASDAQ EOLS opened at $4.33 on Tuesday. The company has a market capitalization of $280.67 million, a P/E ratio of -4.71 and a beta of 1.12. The company’s 50 day simple moving average is $5.44 and its 200 day simple moving average is $6.32. Evolus has a 12 month low of $4.09 and a 12 month high of $14.94.

Wall Street Analyst Weigh In

EOLS has been the subject of a number of analyst reports. Mizuho set a $15.00 price objective on shares of Evolus in a research note on Wednesday, February 4th. Needham & Company LLC reissued a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. Wall Street Zen raised Evolus from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. HC Wainwright reduced their price target on shares of Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Finally, BTIG Research lowered their price target on Evolus from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $17.50.

Insider Transactions at Evolus

In other Evolus news, insider David Moatazedi sold 10,539 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $7.15, for a total value of $75,353.85. Following the completion of the sale, the insider owned 354,388 shares in the company, valued at approximately $2,533,874.20. This represents a 2.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC purchased a new position in Evolus in the fourth quarter worth about $151,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Evolus during the 4th quarter valued at approximately $144,000. Wellington Management Group LLP lifted its position in Evolus by 5.9% in the fourth quarter. Wellington Management Group LLP now owns 195,160 shares of the company’s stock worth $1,298,000 after buying an additional 10,850 shares during the last quarter. Quadrature Capital Ltd boosted its stake in Evolus by 29.9% during the fourth quarter. Quadrature Capital Ltd now owns 18,095 shares of the company’s stock worth $120,000 after buying an additional 4,168 shares during the period. Finally, Oxford Asset Management LLP bought a new position in Evolus during the fourth quarter valued at $152,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.